<DOC>
	<DOCNO>NCT00737633</DOCNO>
	<brief_summary>This study extension study ongoing 1 year . The purpose open label study see well type 2 diabetic respond VI-0521 ( phentermine/topiramate ) control blood sugar safe VI-0521 extend period time . All subject eligible enroll study receive study drug .</brief_summary>
	<brief_title>Open-Label Study Evaluate Long-Term Safety Efficacy VI-0521 Type 2 Diabetic Adults</brief_title>
	<detailed_description />
	<criteria>Have complete qualify DM230 trial If female childbearing potential , subject must use adequate contraception Provide write informed consent Be willing able comply schedule study visit , treatment plan , lab test study procedure Be great 80 % compliant study medication use last three visit DM230 Subjects develop one morbidity DM230 trial would pose safety concern</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Glycemic Control</keyword>
</DOC>